Results 171 to 180 of about 172,625 (265)

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source

Crofton Risk and Relative Transactional Entropy. [PDF]

Entropy (Basel)
Makowski M, Piotrowski EW.
europepmc   +1 more source

Financial impact of non-communicable diseases on households with older adults in india: a mixed methods study. [PDF]

BMC Geriatr
Prince D E A, Kodali PB.
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Prevalence and Predictors of Adolescent Tobacco Use in the Russian Federation: Insights From a Nationwide Survey. [PDF]

Public Health Chall
Bukhari AAS, Shah SS, Sleiay M, Ali MM.
europepmc   +1 more source

The Effectiveness and Civilian Perceptions of E-Money

Proceedings of the 2nd International Research Conference on Economics and Business, 2018
Bagus Shandy Narmaditya, Dwi Wulandari, Hanum Rida Almira   +2 more
openaire   +1 more source

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden, Miriam G. Mooij, Matthijs de Hoog, Saskia N. de Wildt   +3 more
wiley   +1 more source

Readiness and implications for adopting digitized payment of community health workers: a qualitative study of Benin and Uganda. [PDF]

Front Health Serv
Kabayambi JP, Bello K, Kisakye AN, Sekpon VD, Boyi-Hounsou C, Aweko J, Kiracho EE, Waiswa P, Padonou G, Okuonzi SA.   +9 more
europepmc   +1 more source

Zuranolone: A case study in (regulatory) rush to judgement?

British Journal of Clinical Pharmacology, EarlyView.
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove, Milutin Kostic, Barbara Mintzes, Gianna D'Ambrozio, Allen Shaughnessy   +4 more
wiley   +1 more source

Gender trends in youth tobacco and nicotine use in Georgia across GYTS rounds, 2014-23. [PDF]

Eur J Public Health
Gvinianidze K, Bakhturidze G, Abuladze T, Dekanosidze A, Sturua L, Gegenava V, Tarasenko Y, Ciobanu A.   +7 more
europepmc   +1 more source